15 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 3 Phase 1, 2 Not applicable, 1 Phase 2, 1 Phase 3, 1 Phase 4.
By phase and status
Follow Hikma Pharmaceuticals LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
Azacitidine - Acute Myeloid Leukemia | Not applicable | Active not recruiting | Hikma Pharmaceuticals LLC | 20 | 2025-04-29 | 2026-01-14 |
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
Azacitidine, Onureg - Acute Myeloid Leukaemia | Phase 1 | Completed | Hikma Pharmaceuticals LLC | 32 | 2024-05-02 | 2025-09-26 |
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Carcemia, Glivec - Chronic Myeloid Leukemia | | Recruiting | Hikma Pharmaceuticals LLC | 240 | 2022-07-20 | 2025-03-26 |
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
Fingolimod - Relapsing-Remitting Multiple Sclerosis | | Completed | Hikma Pharmaceuticals LLC | 30 | 2022-01-19 | 2024-08-23 |
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
WinterLight Mobile Phone Speech Analysis - Schizophrenia | | Completed | Hikma Pharmaceuticals LLC | 57 | 2021-11-09 | 2023-09-22 |
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
Dimethyl Fumarate (DMF) - Relapsing Remitting Multiple Sclerosis | | Completed | Hikma Pharmaceuticals LLC | 160 | 2021-02-23 | 2023-09-22 |
Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)
Ekmasonid, Uceris (first dose), Uceris (second dose) - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 30 | 2020-09-17 | 2021-04-22 |
Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).
Sphingomod, Gilenya - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 34 | 2020-08-10 | 2020-12-08 |
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Dasatinib - Chronic Myelogenous Leukemia | Phase 2 | Completed | Hikma Pharmaceuticals LLC | 56 | 2018-11-05 | 2023-09-22 |
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
Infliximab - Inflammatory Bowel Diseases, Crohn Disease | | Completed | Hikma Pharmaceuticals LLC | 157 | 2018-08-26 | 2021-02-23 |
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
Imatinib - Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase | | Completed | Hikma Pharmaceuticals LLC | 173 | 2018-05-13 | 2021-02-23 |
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
Pemetrexed, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 4 | Terminated | Hikma Pharmaceuticals LLC | 9 | 2018-02-28 | 2020-03-05 |
Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
Biosimilar Infliximab - Rheumatoid Arthritis | | Completed | Hikma Pharmaceuticals LLC | 22 | 2017-03-23 | 2020-03-04 |
Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy
Ferric carboxymaltose (FCM) - Anemia, Cancer | Not applicable | Completed | King Hussein Cancer Center | 84 | 2016-06-15 | 2022-01-04 |
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
Rosuvastatin - Primary Hypercholesterolemia | | Completed | Hikma Pharmaceuticals LLC | 317 | 2014-11-01 | 2018-05-07 |
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan
Mycophenolate Mofetil - Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant | | Completed | Hikma Pharmaceuticals LLC | 12 | 2014-10-01 | 2018-05-08 |
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
Imatinib - Chronic Myeloid Leukemia, Chronic Phase | | Completed | Hikma Pharmaceuticals LLC | 91 | 2012-08-01 | 2016-11-30 |
Schistosoma Haematobium Infections and Praziquantel
praziquantel - Schistosomiasis | Phase 3 | Completed | University of Khartoum | 520 | 2008-08-01 | 2013-01-17 |
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
HIV Infections, Hepatitis B | | Recruiting | Syneos Health | 24258 | 1989-01-01 | 2025-04-01 |
Conditions studied
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myeloid, Chronic-Phase (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Neoplasms (2) · Neurologic Manifestations (2) · Anemia (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Behavioral Symptoms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Colitis, Ulcerative (1)
Interventions
Imatinib Mesylate (3) · Azacitidine (2) · CT-P13 (2) · Fingolimod Hydrochloride (2) · Budesonide (1) · Dasatinib (1) · Dimethyl Fumarate (1) · Erlotinib Hydrochloride (1) · Infliximab (1) · Mycophenolic Acid (1) · Pemetrexed (1) · Praziquantel (1) · Rosuvastatin Calcium (1) · elsulfavirine (1) · ferric carboxymaltose (1)
Countries
Egypt (7) · Jordan (7) · Saudi Arabia (4) · Algeria (2) · Lebanon (2) · Sudan (1) · Tunisia (1) · United Arab Emirates (1) · United States (1)
Top investigators
Ahmed Elshafeey, Ph.D. Pharma (2) · Abdallah Abbadi, Professor (1) · Jessica D Albano, PhD, MPH (1)
Results publications
PMID 21729382, PMID 26269220, PMID 26687320, PMID 32952616